Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The combination of cetirizine and salbutamol is a therapeutic approach for respiratory conditions with both allergic and bronchoconstrictive components. **Cetirizine** is a second-generation H1-antihistamine that selectively inhibits peripheral H1 receptors, with minimal sedative effects due to reduced brain penetration. It manages symptoms of allergic conditions, including allergic asthma. **Salbutamol** (also known as albuterol) is a short-acting beta-2 adrenergic receptor agonist used for rapid bronchodilation in conditions like asthma. When used together, studies suggest: * **Synergistic Bronchodilation**: Cetirizine can enhance salbutamol's relaxant effect on bronchi. * **Additive Bronchodilatory Effect**: Clinical studies indicate an additive bronchodilatory effect without potentiation or inhibition. * **Complementary Duration**: Cetirizine may prolong bronchodilatory action beyond salbutamol's typical duration. The combination addresses both the allergic component via cetirizine's antihistamine action and bronchospasm through salbutamol's bronchodilatory effect. Fast-disintegrating tablet formulations have been developed for ease of administration, particularly for pediatric and geriatric patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cetirizine + Salbutamol.